A zebrafish model of congenital disorders of glycosylation with phosphomannose isomerase deficiency reveals an early opportunity for corrective mannose supplementation
Open Access
- 1 January 2012
- journal article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 6 (1), 95-105
- https://doi.org/10.1242/dmm.010116
Abstract
Summary Individuals with congenital disorders of glycosylation (CDG) have recessive mutations in genes required for protein N-glycosylation, resulting in multi-systemic disease. Despite the well-characterized biochemical consequences in these individuals, the underlying cellular defects that contribute to CDG are not well understood. Synthesis of the lipid-linked oligosaccharide (LLO), which serves as the sugar donor for the N-glycosylation of secretory proteins, requires conversion of fructose-6-phosphate to mannose-6-phosphate via the phosphomannose isomerase (MPI) enzyme. Individuals who are deficient in MPI present with bleeding, diarrhea, edema, gastrointestinal bleeding and liver fibrosis. MPI-CDG patients can be treated with oral mannose supplements, which is converted to mannose-6-phosphate through a minor complementary metabolic pathway, restoring protein glycosylation and ameliorating most symptoms, although liver disease continues to progress. Because Mpi deletion in mice causes early embryonic lethality and thus is difficult to study, we used zebrafish to establish a model of MPI-CDG. We used a morpholino to block mpi mRNA translation and established a concentration that consistently yielded 13% residual Mpi enzyme activity at 4 days post-fertilization (dpf), which is within the range of MPI activity detected in fibroblasts from MPI-CDG patients. Fluorophore-assisted carbohydrate electrophoresis detected decreased LLO and N-glycans in mpi morphants. These deficiencies resulted in 50% embryonic lethality by 4 dpf. Multi-systemic abnormalities, including small eyes, dysmorphic jaws, pericardial edema, a small liver and curled tails, occurred in 82% of the surviving larvae. Importantly, these phenotypes could be rescued with mannose supplementation. Thus, parallel processes in fish and humans contribute to the phenotypes caused by Mpi depletion. Interestingly, mannose was only effective if provided prior to 24 hpf. These data provide insight into treatment efficacy and the broader molecular and developmental abnormalities that contribute to disorders associated with defective protein glycosylation.This publication has 43 references indexed in Scilit:
- Neurology of inherited glycosylation disordersThe Lancet Neurology, 2012
- Mannose-6-phosphate regulates destruction of lipid-linked oligosaccharidesMolecular Biology of the Cell, 2011
- Activating transcription factor 6 plays protective and pathological roles in steatosis due to endoplasmic reticulum stress in zebrafishHepatology, 2011
- Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patientsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- New school in liver development: Lessons from zebrafishHepatology, 2009
- An enzymatic fluorimetric assay for glucose-6-phosphate: Application in an in vitro Warburg-like effectAnalytical Biochemistry, 2009
- Alteration of protein glycosylation in liver diseasesJournal of Hepatology, 2009
- p53 Activation by Knockdown TechnologiesPLoS Genetics, 2007
- A Novel Disorder of N-Glycosylation Due to Phosphomannose Isomerase DeficiencyBiochemical and Biophysical Research Communications, 1998
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976